Pieris Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PIRS)

$5.78 0.37 (6.84 %)
(As of 11/17/2017 12:18 PM ET)
Previous Close$5.41
Today's Range$5.45 - $5.87
52-Week Range$1.34 - $6.58
Volume536,000 shs
Average Volume636,335 shs
Market Capitalization$242.34 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68

About Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:PIRS
  • CUSIP: N/A
  • Web: www.pieris.com
Debt:
  • Current Ratio: 2.44%
  • Quick Ratio: 2.87%
Sales & Book Value:
  • Annual Sales: $5.83 million
  • Price / Sales: 44.41
  • Book Value: $0.10 per share
  • Price / Book: 57.80
Profitability:
  • Trailing EPS: ($0.74)
  • Net Income: ($22,790,000.00)
  • Net Margins: -321.83%
  • Return on Equity: -221.93%
  • Return on Assets: -42.02%
Misc:
  • Employees: 52
  • Outstanding Shares: 44,790,000
 
Frequently Asked Questions for Pieris Pharmaceuticals (NASDAQ:PIRS)

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) posted its earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. The biotechnology company earned $3.93 million during the quarter, compared to analysts' expectations of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. Pieris Pharmaceuticals's quarterly revenue was up 400.3% on a year-over-year basis. View Pieris Pharmaceuticals' Earnings History.

Where is Pieris Pharmaceuticals' stock going? Where will Pieris Pharmaceuticals' stock price be in 2017?

3 analysts have issued 12-month price objectives for Pieris Pharmaceuticals' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Pieris Pharmaceuticals' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Pieris Pharmaceuticals.

Who are some of Pieris Pharmaceuticals' key competitors?

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the folowing people:

  • Chau Quang Khuong, Independent Chairman of the Board (Age 41)
  • Stephen S. Yoder, President, Chief Executive Officer, Director (Age 39)
  • Lance E. Thibault, Acting Chief Financial Officer (Age 50)
  • Claude Knopf, Senior Vice President, Chief Business Officer
  • Louis A. Matis M.D., Senior Vice President and Chief Development Officer (Age 54)
  • Julian Adams, Director (Age 61)
  • Jean-Pierre Bizzari M.D., Director (Age 62)
  • James A. Geraghty, Director (Age 62)
  • Christopher P. Kiritsy, Director (Age 49)
  • Steven Prelack, Independent Director (Age 57)

Who owns Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (2.26%), JPMorgan Chase & Co. (0.23%), First Quadrant L P CA (0.19%), New York State Common Retirement Fund (0.07%) and Wells Fargo & Company MN (0.04%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis and Stephen S Yoder. View Institutional Ownership Trends for Pieris Pharmaceuticals.

Who sold Pieris Pharmaceuticals stock? Who is selling Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD.. View Insider Buying and Selling for Pieris Pharmaceuticals.

Who bought Pieris Pharmaceuticals stock? Who is buying Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., First Quadrant L P CA, Wells Fargo & Company MN and New York State Common Retirement Fund. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis and Stephen S Yoder. View Insider Buying and Selling for Pieris Pharmaceuticals.

How do I buy Pieris Pharmaceuticals stock?

Shares of Pieris Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of Pieris Pharmaceuticals stock can currently be purchased for approximately $5.78.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $242.34 million and generates $5.83 million in revenue each year. The biotechnology company earns ($22,790,000.00) in net income (profit) each year or ($0.74) on an earnings per share basis. Pieris Pharmaceuticals employs 52 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]


MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Pieris Pharmaceuticals (NASDAQ:PIRS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (55.71% upside)
Consensus Price Target History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Price Target History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Analysts' Ratings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017HC WainwrightReiterated RatingBuy$9.00N/AView Rating Details
5/30/2017Rodman & RenshawInitiated CoverageBuy -> Buy$9.00HighView Rating Details
4/12/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$9.00LowView Rating Details
9/28/2016Roth CapitalReiterated RatingBuy$6.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$10.00 -> $9.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Earnings by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Earnings History by Quarter for Pieris Pharmaceuticals (NASDAQ PIRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.21)($0.16)$1.52 million$3.93 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.16($0.19)$32.30 million$1.34 millionViewN/AView Earnings Details
8/10/2016Q216($0.15)($0.14)$1.08 million$1.07 millionViewN/AView Earnings Details
5/11/2016Q116($0.12)($0.10)$6.40 million$1.25 millionViewN/AView Earnings Details
3/23/2016Q415($0.12)($0.07)$3.27 million$2.14 millionViewN/AView Earnings Details
11/11/2015Q315($0.11)($0.10)$0.23 million$0.42 millionViewN/AView Earnings Details
8/12/2015Q215($0.14)($0.12)$0.25 million$0.16 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)
2017 EPS Consensus Estimate: $0.05
2018 EPS Consensus Estimate: ($0.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.52$0.52$0.52
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.02)($0.02)($0.02)
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.22)($0.22)($0.22)
Q3 20181($0.20)($0.20)($0.20)
Q4 20181($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Pieris Pharmaceuticals (NASDAQ PIRS)
Insider Ownership Percentage: 4.05%
Institutional Ownership Percentage: 50.59%
Insider Trades by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Insider Trades by Quarter for Pieris Pharmaceuticals (NASDAQ PIRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2017Allan ReineInsiderBuy65,000$4.82$313,300.00View SEC Filing  
8/17/2017James A GeraghtyDirectorBuy10,000$4.82$48,200.00View SEC Filing  
6/14/2016Louis MatisSVPBuy10,000$1.70$17,000.00View SEC Filing  
6/13/2016Darlene M Deptula-HicksCFOBuy5,000$1.66$8,300.00View SEC Filing  
6/13/2016Stephen S YoderCEOBuy6,000$1.68$10,080.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pieris Pharmaceuticals (NASDAQ:PIRS)
Latest Headlines for Pieris Pharmaceuticals (NASDAQ PIRS)
Source:
DateHeadline
ETFs with exposure to Pieris Pharmaceuticals, Inc. : November 9, 2017ETFs with exposure to Pieris Pharmaceuticals, Inc. : November 9, 2017
finance.yahoo.com - November 12 at 11:42 AM
Edited Transcript of PIRS earnings conference call or presentation 9-Nov-17 3:00pm GMTEdited Transcript of PIRS earnings conference call or presentation 9-Nov-17 3:00pm GMT
finance.yahoo.com - November 12 at 11:42 AM
HC Wainwright Reiterates Buy Rating for Pieris Pharmaceuticals, Inc. (PIRS)HC Wainwright Reiterates Buy Rating for Pieris Pharmaceuticals, Inc. (PIRS)
www.americanbankingnews.com - November 12 at 12:58 AM
Pieris Pharmaceuticals, Inc. (PIRS) Announces Quarterly  Earnings ResultsPieris Pharmaceuticals, Inc. (PIRS) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 9 at 6:04 PM
Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate UpdatePieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update
finance.yahoo.com - November 9 at 11:35 AM
Pieris Pharmaceuticals reports 3Q lossPieris Pharmaceuticals reports 3Q loss
finance.yahoo.com - November 9 at 11:35 AM
Pieris Pharmaceuticals, Inc. to Host Earnings CallPieris Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 11:35 AM
$1.73 Million in Sales Expected for Pieris Pharmaceuticals, Inc. (PIRS) This Quarter$1.73 Million in Sales Expected for Pieris Pharmaceuticals, Inc. (PIRS) This Quarter
www.americanbankingnews.com - November 7 at 4:36 AM
Pieris Pharmaceuticals, Inc. (PIRS) Expected to Post Earnings of -$0.21 Per SharePieris Pharmaceuticals, Inc. (PIRS) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - November 5 at 7:16 AM
Pieris Pharmaceuticals to Host Third Quarter 2017 Investor Call and Corporate Update on November 9, 2017Pieris Pharmaceuticals to Host Third Quarter 2017 Investor Call and Corporate Update on November 9, 2017
finance.yahoo.com - November 4 at 8:54 AM
Pieris Pharmaceuticals to Present at Investor Conferences in NovemberPieris Pharmaceuticals to Present at Investor Conferences in November
finance.yahoo.com - November 2 at 7:43 AM
ETFs with exposure to Pieris Pharmaceuticals, Inc. : October 27, 2017ETFs with exposure to Pieris Pharmaceuticals, Inc. : October 27, 2017
finance.yahoo.com - October 27 at 3:17 PM
Pieris Pharmaceuticals, Inc. (PIRS) Expected to Announce Quarterly Sales of $1.73 MillionPieris Pharmaceuticals, Inc. (PIRS) Expected to Announce Quarterly Sales of $1.73 Million
www.americanbankingnews.com - October 18 at 5:20 AM
ETFs with exposure to Pieris Pharmaceuticals, Inc. : October 17, 2017ETFs with exposure to Pieris Pharmaceuticals, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 4:04 PM
Commit To Buy Pieris Pharmaceuticals At $5, Earn 26.1% Annualized Using OptionsCommit To Buy Pieris Pharmaceuticals At $5, Earn 26.1% Annualized Using Options
www.nasdaq.com - October 14 at 6:47 AM
Is It Time To Buy Pieris Pharmaceuticals Inc (PIRS)?Is It Time To Buy Pieris Pharmaceuticals Inc (PIRS)?
finance.yahoo.com - October 14 at 6:47 AM
Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical DevelopmentPieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
finance.yahoo.com - October 12 at 8:18 AM
ETFs with exposure to Pieris Pharmaceuticals, Inc. : October 6, 2017ETFs with exposure to Pieris Pharmaceuticals, Inc. : October 6, 2017
finance.yahoo.com - October 7 at 7:20 AM
Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 4:23 PM
Insiders Were Right: PIRS Makes New 52-Week HighInsiders Were Right: PIRS Makes New 52-Week High
www.thestreet.com - October 3 at 10:46 AM
Pieris Pharmaceuticals, Inc. (PIRS) Given a $9.00 Price Target by HC Wainwright AnalystsPieris Pharmaceuticals, Inc. (PIRS) Given a $9.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - October 2 at 3:50 PM
Pieris Pharma (PIRS) Reports Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343 - StreetInsider.comPieris Pharma (PIRS) Reports Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343 - StreetInsider.com
www.streetinsider.com - October 2 at 10:35 AM
Pieris Pharmaceuticals, Inc. (PIRS) Short Interest UpdatePieris Pharmaceuticals, Inc. (PIRS) Short Interest Update
www.americanbankingnews.com - September 30 at 3:02 AM
Pieris Pharmaceuticals (PIRS) Presents At LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology - SlideshowPieris Pharmaceuticals (PIRS) Presents At LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology - Slideshow
seekingalpha.com - September 29 at 12:24 PM
Pieris Pharmaceuticals (PIRS) and Opexa Therapeutics (ACER) Critical ReviewPieris Pharmaceuticals (PIRS) and Opexa Therapeutics (ACER) Critical Review
www.americanbankingnews.com - September 29 at 6:24 AM
 Brokerages Expect Pieris Pharmaceuticals, Inc. (PIRS) Will Announce Earnings of -$0.21 Per Share Brokerages Expect Pieris Pharmaceuticals, Inc. (PIRS) Will Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - September 28 at 12:32 AM
Is Pieris Pharmaceuticals Inc (PIRS) Undervalued?Is Pieris Pharmaceuticals Inc (PIRS) Undervalued?
finance.yahoo.com - September 16 at 7:48 AM
Pieris Pharmaceuticals (PIRS) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowPieris Pharmaceuticals (PIRS) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 9:15 AM
Pieris Pharmaceuticals, Inc. (PIRS) Given Average Rating of "Buy" by BrokeragesPieris Pharmaceuticals, Inc. (PIRS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 5 at 6:28 AM
Pieris Pharmaceuticals: Favorable Collaboration Terms Point To Continued UpsidePieris Pharmaceuticals: Favorable Collaboration Terms Point To Continued Upside
seekingalpha.com - August 25 at 10:06 AM
Oppenheimer Holdings Comments on Pieris Pharmaceuticals, Inc.s FY2017 Earnings (PIRS)Oppenheimer Holdings Comments on Pieris Pharmaceuticals, Inc.'s FY2017 Earnings (PIRS)
www.americanbankingnews.com - August 21 at 5:10 AM
Insider Buying: Pieris Pharmaceuticals, Inc. (PIRS) Director Acquires 10,000 Shares of StockInsider Buying: Pieris Pharmaceuticals, Inc. (PIRS) Director Acquires 10,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:48 PM
Pieris Pharmaceuticals, Inc. (PIRS) Insider Allan Reine Buys 65,000 SharesPieris Pharmaceuticals, Inc. (PIRS) Insider Allan Reine Buys 65,000 Shares
www.americanbankingnews.com - August 17 at 10:26 PM
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Given a $9.00 Price Target by HC Wainwright AnalystsPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Given a $9.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 13 at 3:32 PM
Pieris Pharmaceuticals, Inc. (PIRS) Receives Average Recommendation of "Buy" from BrokeragesPieris Pharmaceuticals, Inc. (PIRS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 11 at 5:06 PM
Pieris Pharma (PIRS) Appoints Allan Reine as CFOPieris Pharma (PIRS) Appoints Allan Reine as CFO
www.streetinsider.com - August 11 at 7:33 AM
Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial OfficerPieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial Officer
finance.yahoo.com - August 11 at 7:33 AM
Edited Transcript of PIRS earnings conference call or presentation 10-Aug-17 2:00pm GMTEdited Transcript of PIRS earnings conference call or presentation 10-Aug-17 2:00pm GMT
finance.yahoo.com - August 11 at 7:33 AM
Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate UpdatePieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate Update
finance.yahoo.com - August 10 at 6:52 AM
Pieris Pharmaceuticals reports 2Q lossPieris Pharmaceuticals reports 2Q loss
finance.yahoo.com - August 10 at 6:52 AM
Pieris Pharmaceuticals, Inc. (PIRS) Expected to Post Earnings of -$0.14 Per SharePieris Pharmaceuticals, Inc. (PIRS) Expected to Post Earnings of -$0.14 Per Share
www.americanbankingnews.com - August 3 at 10:14 AM
Pieris Pharmaceuticals to Host Second Quarter 2017 Investor Call and Corporate Update on August 10, 2017Pieris Pharmaceuticals to Host Second Quarter 2017 Investor Call and Corporate Update on August 10, 2017
finance.yahoo.com - August 1 at 4:26 PM
Pieris Pharmaceuticals, Inc. (PIRS) Sees Large Increase in Short InterestPieris Pharmaceuticals, Inc. (PIRS) Sees Large Increase in Short Interest
www.americanbankingnews.com - July 16 at 7:14 AM
OpCo On Biotech: Our Bullishness Is UnabatedOpCo On Biotech: 'Our Bullishness Is Unabated'
finance.yahoo.com - July 13 at 7:59 AM
Pieris Pharmaceuticals Announces Results from 2017 Annual Meeting of Stockholders and Provides Update on Therapeutic ProgramsPieris Pharmaceuticals Announces Results from 2017 Annual Meeting of Stockholders and Provides Update on Therapeutic Programs
finance.yahoo.com - July 6 at 7:59 AM
ETFs with exposure to Pieris Pharmaceuticals, Inc. : July 4, 2017ETFs with exposure to Pieris Pharmaceuticals, Inc. : July 4, 2017
finance.yahoo.com - July 5 at 9:36 AM
Health Care Stocks Are Crushing the S&P 500 (JNJ, SNY, AZN) - InvestopediaHealth Care Stocks Are Crushing the S&P 500 (JNJ, SNY, AZN) - Investopedia
www.investopedia.com - June 19 at 10:25 AM
Pieris Pharma (PIRS) Reports Expiration of HSR Waiting Period for Collaboration with AstraZeneca (AZN)Pieris Pharma (PIRS) Reports Expiration of HSR Waiting Period for Collaboration with AstraZeneca (AZN)
www.streetinsider.com - June 12 at 6:52 PM
Pieris Pharmaceuticals (PIRS) Presents At Jefferies 2017 Global Healthcare Conference - SlideshowPieris Pharmaceuticals (PIRS) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 6:52 PM
Gainers & Losers Of May 3: PIRS, MYGN, XENT, RXDX, SPPI...Gainers & Losers Of May 3: PIRS, MYGN, XENT, RXDX, SPPI...
www.finanznachrichten.de - May 5 at 12:26 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Pieris Pharmaceuticals (NASDAQ PIRS) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.